Nima Sharifi

8.7k total citations · 2 hit papers
131 papers, 5.5k citations indexed

About

Nima Sharifi is a scholar working on Pulmonary and Respiratory Medicine, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Nima Sharifi has authored 131 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Pulmonary and Respiratory Medicine, 74 papers in Endocrinology, Diabetes and Metabolism and 48 papers in Molecular Biology. Recurrent topics in Nima Sharifi's work include Prostate Cancer Treatment and Research (99 papers), Hormonal and reproductive studies (70 papers) and Sexual Differentiation and Disorders (29 papers). Nima Sharifi is often cited by papers focused on Prostate Cancer Treatment and Research (99 papers), Hormonal and reproductive studies (70 papers) and Sexual Differentiation and Disorders (29 papers). Nima Sharifi collaborates with scholars based in United States, Canada and China. Nima Sharifi's co-authors include Richard J. Auchus, Charles S. Dai, Jeffrey M. McManus, Hannelore V. Heemers, Kai‐Hsiung Chang, Kunal Desai, William L. Dahut, Rui Li, Mohammad Alyamani and William L. Farrar and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Nima Sharifi

124 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Androgen Deprivation Therapy for Prostate Cancer

2005 813 citations Nima Sharifi profile →
Hormonal Therapy for Prostate Cancer

2021 251 citations Jeffrey M. McManus, Nima Sharifi et al. profile →

Peers

Nima Sharifi

PRM

EDM

ONCOL

Natasha Kyprianou United States

Alfred Hobisch Austria

Masaki Shiota Japan

Joy C. Yang United States

Cynthia Heinlein United States

Peng Hou China

Alice C. Levine United States

Akira Yokomizo Japan

Paul E. Goss Canada

Natasha Kyprianou United States

Nima Sharifi

2.7k ×0.8

PRM

3.9k ×2.1

719 ×0.4

EDM

1.7k ×1.4

2.0k ×2.0

ONCOL

Citations per year, relative to Nima Sharifi Nima Sharifi (= 1×) peers Natasha Kyprianou

Countries citing papers authored by Nima Sharifi

Since Specialization

Citations

This map shows the geographic impact of Nima Sharifi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nima Sharifi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nima Sharifi more than expected).

Fields of papers citing papers by Nima Sharifi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nima Sharifi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nima Sharifi. The network helps show where Nima Sharifi may publish in the future.

Co-authorship network of co-authors of Nima Sharifi

This figure shows the co-authorship network connecting the top 25 collaborators of Nima Sharifi. A scholar is included among the top collaborators of Nima Sharifi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nima Sharifi. Nima Sharifi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McKay, Rana R., et al.. (2024). HSD3B1, prostate cancer mortality and modifiable outcomes. Nature Reviews Urology. 22(5). 313–320. 5 indexed citations

Sharifi, Nima, Arun Azad, Jason W.D. Hearn, et al.. (2024). HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES. Cell Reports Medicine. 5(8). 101644–101644. 4 indexed citations

Hardaway, Aimalie, Timothy D. Smile, Elai Davicioni, et al.. (2023). Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer. Journal of Clinical Investigation. 133(22). 5 indexed citations

Cui, Di, Jianneng Li, Ziqi Zhu, et al.. (2023). Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation. Journal of Clinical Investigation. 133(7). 25 indexed citations

Alyamani, Mohammad, et al.. (2023). Approaches to assessing 3β-hydroxysteroid dehydrogenase-1. Methods in enzymology on CD-ROM/Methods in enzymology. 689. 89–119. 4 indexed citations

Baratchian, Mehdi, Ritika Tiwari, Sirvan Khalighi, et al.. (2022). H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer. Proceedings of the National Academy of Sciences. 119(21). e2114324119–e2114324119. 35 indexed citations

Qin, Liang, Yoon‐Mi Chung, Ziqi Zhu, et al.. (2022). Hypoxia-Reoxygenation Couples 3βHSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in Prostate Cancer. Cancer Research. 82(13). 2417–2430. 9 indexed citations

Mostaghel, Elahe A., Brett T. Marck, Orpheus Kolokythas, et al.. (2021). Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. Clinical Cancer Research. 27(21). 6001–6011. 17 indexed citations

Li, Jianneng, Mohammad Alyamani, Navin Sabharwal, et al.. (2021). Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. Science Translational Medicine. 13(595). 17 indexed citations

10.

Kruse, Megan, Mona Patel, Jeffrey M. McManus, et al.. (2021). Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer. JCI Insight. 6(20). 15 indexed citations

11.

Reichard, Chad A., Zeneng Wang, Xun Jia, et al.. (2021). Gut Microbiome–Dependent Metabolic Pathways and Risk of Lethal Prostate Cancer: Prospective Analysis of a PLCO Cancer Screening Trial Cohort. Cancer Epidemiology Biomarkers & Prevention. 31(1). 192–199. 35 indexed citations

12.

Brubaker, Gregory, Jennifer Major, Chase Neumann, et al.. (2020). Uptake of high-density lipoprotein by scavenger receptor class B type 1 is associated with prostate cancer proliferation and tumor progression in mice. Journal of Biological Chemistry. 295(24). 8252–8261. 31 indexed citations

13.

Gao, Xiaomei, Charles S. Dai, Shengsong Huang, et al.. (2018). Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression. Clinical Cancer Research. 25(4). 1291–1301. 41 indexed citations

14.

Mostaghel, Elahe A., Eunpi Cho, Ailin Zhang, et al.. (2017). Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clinical Cancer Research. 23(16). 4592–4601. 31 indexed citations

15.

Dai, Charles S., Yoon-Mi Chung, Evan Kovac, et al.. (2017). Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues. Clinical Cancer Research. 23(20). 6351–6362. 38 indexed citations

16.

Sharifi, Nima. (2015). CYP17A1 inhibitor failure—lessons for future drug development. Nature Reviews Urology. 12(5). 245–246. 5 indexed citations

17.

Li, Rui, Kamalesh Kumar Sharma, Kai‐Hsiung Chang, et al.. (2012). Abiraterone Inhibits 3β-Hydroxysteroid Dehydrogenase: A Rationale for Increasing Drug Exposure in Castration-Resistant Prostate Cancer. Clinical Cancer Research. 18(13). 3571–3579. 81 indexed citations

18.

Sharifi, Nima, et al.. (2011). SOD Mimetics: A Novel Class of Androgen Receptor Inhibitors That Suppresses Castration-Resistant Growth of Prostate Cancer. Molecular Cancer Therapeutics. 11(1). 87–97. 32 indexed citations

19.

Chang, Kai‐Hsiung, Rui Li, Mahboubeh Papari-Zareei, et al.. (2011). Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proceedings of the National Academy of Sciences. 108(33). 13728–13733. 270 indexed citations

20.

Hamada, Akinobu, Tristan M. Sissung, Douglas K. Price, et al.. (2008). Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer. Clinical Cancer Research. 14(11). 3312–3318. 153 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact